Drug Makers Stocks Under Scanner — Alliqua BioMedical, AbbVie, Johnson & Johnson, and Merck

NEW YORK, May 15, 2017 /PRNewswire/ —

Featured on Stock-Callers.com today are these four major players in the Drug Manufacturers space: Alliqua BioMedical Inc. (NASDAQ: ALQA), AbbVie Inc. (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Merck & Co. Inc. (NYSE: MRK). The Pharmaceutical industry consists of companies that research, develop, market, and distribute drugs for nearly every therapeutic need. You can access our complimentary research reports on these stocks now at:

http://stock-callers.com/registration

Alliqua BioMedical

Yardley, Pennsylvania-based Alliqua BioMedical Inc.’s stock finished last Friday’s session 2.61% lower at $0.37 with a total trading volume of 55,724 shares. The Company’s shares are trading below their 50-day moving average by 27.87%. Shares of the Company, which commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue, have a Relative Strength Index (RSI) of 36.67.

On May 09th, 2017, Alliqua BioMedical announced financial results for Q1 ended March 31st, 2017. Total revenue from continuing operations increased 16% year-over-year to $4.6 million; product revenue from continuing operations increased 28% year-over-year to $4.4 million; gross margin was 64% for Q1 2017, compared to 60% in the same period last year; and adjusted EBITDA loss decreased by $1.8 million, or 36% year-over-year, to ($3.2) million. Visit us today and download your complete report on ALQA for free at:

http://stock-callers.com/registration/?symbol=ALQA
AbbVie

On Friday, shares in North Chicago, Illinois-based AbbVie Inc. ended the session 1.16% higher at $66.06. The stock recorded a trading volume of 6.06 million shares, which was higher than its three months average volume of 6.03 million shares. The Company’s shares have gained 2.63% in the last one month, 10.42% in the previous three months, and 7.62% on an YTD basis. The stock is trading 1.84% above its 50-day moving average and 6.41% above its 200-day moving average. Moreover, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 54.02.

On May 05th, 2017, AbbVie announced that it will participate in the UBS Global Healthcare Conference on Monday, May 22nd, 2017. Richard A. Gonzalez, Chairman of the board and CEO, will present at 7:00 a.m. CT. A live audio webcast of the presentation will be accessible on the Company’s Investor Relations website. The complimentary research report on ABBV can be accessed at:

http://stock-callers.com/registration/?symbol=ABBV
Johnson & Johnson

New Brunswick, New Jersey-based Johnson & Johnson’s shares gained 0.36%, closing the session at $123.64 with a total trading volume of 4.10 million shares. The stock has gained 8.00% over the previous three months and 8.03% on an YTD basis. Shares of the Company are trading 4.70% above their 200-day moving average. Additionally, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 45.75.

On May 11th, 2017, Johnson & Johnson announced that it will participate in the Jefferies 2017 Global Healthcare Conference on Thursday, June 08th, 2017, at the Grand Hyatt New York. Alex Gorsky, Chairman and CEO, will represent the Company in a session scheduled at 10:00 a.m. ET. This webcast will be available on the Company’s website. Register for free on Stock-Callers.com and download the PDF research report on JNJ at:

http://stock-callers.com/registration/?symbol=JNJ
Merck

Last Friday at the close, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 10.30 million shares, which was above their three months average volume of 9.19 million shares. The stock ended the session 1.33% lower at $63.57. The Company’s shares have advanced 0.82% in the past month and 8.76% since the start of this year. The stock is trading above its 200-day moving average by 2.86%. Furthermore, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 51.75.

On May 10th, 2017, Merck announced that the US FDA has approved KEYTRUDA® (pembrolizumab), the Company’s anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta®) and carboplatin (pem/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression. Under the FDA’s accelerated approval regulations, this indication is approved based on tumor response rate and progression-free survival. Get free access to your research report on MRK at:

http://stock-callers.com/registration/?symbol=MRK

Be the first to comment on "Drug Makers Stocks Under Scanner — Alliqua BioMedical, AbbVie, Johnson & Johnson, and Merck"

Leave a Reply

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.